Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Associated filings
- 21 Dec 22 424B5 Prospectus supplement for primary offering
- 28 Apr 22 EFFECT Notice of effectiveness
-
22 Mar 22 POS AM Prospectus update (post-effective amendment)
- 21 Mar 22 POSASR Automatic shelf registration (post-effective amendment)
- 6 May 21 424B5 Prospectus supplement for primary offering
- 6 May 21 S-3ASR Automatic shelf registration
Filing view
External links
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated March 21, 2022, with respect to the financial statements of ORIC Pharmaceuticals, Inc., incorporated herein by reference and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
San Diego, CA
March 22, 2022